Recon: Report Finds Hundreds of Thousands of Deaths Tied to Fake Drugs; Pfizer Pays $1M to Settle Misleading Copay Coupon Claims

• Exclusive: Lawsuit says Johnson & Johnson was opioid "kingpin" (Axios)
• Pfizer pays $975,000 to settle charges over misleading copay coupons (STAT) (Law360-$)
• Regeneron/Sanofi wins US approval for expanded use of skin drug (Reuters) (Endpoints) (Press)
• FDA Approves 18th Biosimilar, 4th for Herceptin (Focus) (Reuters) (Press)
• Upcoming market catalysts in Q2 2019 (Nature)
• Abortions by mail: the FDA is going after online pill providers (Vox)
• Alex Azar faces off with Congress today (Politico)
• Hospitals are saving lives with CAR-T. Getting paid is another story (STAT)
• Lilly's combo therapy succeeds in late-stage lung cancer study (Reuters)
• Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover (Endpoints)
• UnitedHealth gives drug discounts directly to consumers in move beyond Trump crackdown (CNBC)
• US Hospitals And Insurers Might Be Forced To Reveal The True Prices They Negotiate (NPR)
• Trump’s 2020 Budget Seeks FDA Tweaks to Increase Generic Competition (Focus)
• Trump’s Budget Offers $291M To Fight HIV In U.S. But Trims Overseas Efforts (KHN)

• Global 'pandemic' of fake drugs killing children worldwide, report says (CNN) (The Guardian) (AJTMH)
• Microsoft moves into biological computing with Station B (Financial Times) (Fierce) (Oxford Biomedica)
• EU Address Complex Clinical Trial Designs In New Guideline (Pink Sheet-$)
• NICE recommends Janssen's Darzalex myeloma combo (Pharmafile)
• Fujifilm grabs Biogen biologics plant in Europe to bolster its CDMO business (Fierce)
• SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma (PharmaTimes)
• Backed by OrbiMed, Lilly and now Advantech, China’s InventisBio loads up $70M to propel cancer, metabolic pipeline (Endpoints)
• UK’s MHRA Offers 6 New No-Deal Brexit Guidances on Importing, Exporting Medicines (Focus)
• ‘Unacceptable secrecy’ surrounds safety warnings by pharma and regulators in Australia (STAT)
• Deadly plague breaks out on Uganda-Congo border, WHO says (Reuters)
• WHO Holds Off on Recalls Following Non-Compliance at Indian Site (Focus)

• Top drugs and companies by sales in 2018 (Nature)
• Drug pricing under the spotlight (Nature)
• Roche, Biogen and AbbVie stake new gene therapy claims (Nature)
• If You Build It, Will They Come? Addressing The Value Equation (LifeSciVC)
• Let’s Play Name That Biosimilar! (FDA Law Blog)
• Deregulating buprenophine prescribing for opioid use disorder will save lives (STAT)
• FDA to Survey Healthcare Professionals on Prescription Drug Marketing (Focus)
• With Alimta patent cliff looming, Lilly plots stronger foothold in frontline NSCLC with Cyramza (Endpoints)
• CANCELLED March 27, 2019: Meeting of the Pulmonary-Allergy Drugs Advisory Committee Meeting Announcement (FDA)
• Another monkey at FDA lab died (Arkansas Democrat)
• Startup Tiburio nabs Avrobio executive Kreher as chief medical officer (Fierce)
• AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres (Endpoints)
• Zafgen’s second try at Prader-Willi syndrome triggers another safety alarm in preclinical tox study (Endpoints)
• FDA’s Focus Has Sharpened on Water Systems in the Wake of Nonsterile Product Microbial Contamination (IPQ)
• Biomarkup: creating or promoting medical tests to drive revenue (STAT)
• Esketamine Faces Challenges In Its Quest To Be A Breakthrough Drug Against Suicidal Ideation (Forbes)
• FDA Pulls Fast-Track Designation for Tonix’s PTSD Treatment (FDANews-$)
• Real-Time Oncology Review Quickly Grows Popular; Venclexta Is Latest To Join Pilot (Pink Sheet-$)

• Allergan files anti-CGRP migraine drug in the US (PharmaTimes)
• GeNeuro touts a mixed set of extension data in a shot at salvaging their failed mid-stage MS drug (Endpoints)
• New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis (Press)
• Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease (Press)
• Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S. (Press)

• CDRH Warns of Device Supply Issues Following Suspension of Illinois Sterilization Facility (Focus)
• Smith & Nephew puts up $660m for Osiris Therapeutics (MassDevice)
• Hill-Rom to acquire Voalte for $195m (MassDevice)
• Alcyone wins breakthrough device status for delivery device (MassDevice)

• Supplemental Report - 2017 Essential Diabetes Drugs (Nevada DHHS)
• Trump proposes e-cigarette user fee to combat youth usage (Reuters)
• Valeant Conflict Wasn't A Crime, Ex-Execs Tell 2nd Circ. (Law360-$)
• Guest Post – Some Good News from California for Companies with Self-Insured Retentions. (Drug & Device Law)

• FDA Advisory Committee Calendar

• EMA Launches Operations in Amsterdam (Focus)
• Provisional NICE nod for Ilumetri (PharmaLetter-$)
• Public unaware of how to verify legitimacy of online pharmacies, survey finds (PharmaTimes)

• Japan eyes India for tech transfer, business collaboration & maximise manpower expertise in lifesciences-healthcare (PharmaBiz)

• Pharma SMEs seek year-long deadline extension for implementation of new labelling norms (PharmaBiz)

• Evaluation of Journal Registration Policies and Prospective Registration of Randomized Clinical Trials of Nonregulated Health Care Interventions (JAMA)